Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers Article

Gronwald, Jacek, Robidoux, Andre, Kim-Sing, Charmaine et al. (2014). Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers . BREAST CANCER RESEARCH AND TREATMENT, 146(2), 421-427. 10.1007/s10549-014-3026-3

Open Access International Collaboration

cited authors

  • Gronwald, Jacek; Robidoux, Andre; Kim-Sing, Charmaine; Tung, Nadine; Lynch, Henry T; Foulkes, William D; Manoukian, Siranoush; Ainsworth, Peter; Neuhausen, Susan L; Demsky, Rochelle; Eisen, Andrea; Singer, Christian F; Saal, Howard; Senter, Leigha; Eng, Charis; Weitzel, Jeffrey; Moller, Pal; Gilchrist, Dawna M; Olopade, Olufunmilayo; Ginsburg, Ophira; Sun, Ping; Huzarski, Tomasz; Lubinski, Jan; Narod, Steven A

sustainable development goals

authors

publication date

  • July 1, 2014

published in

keywords

  • BOWEL PROJECT
  • BRCA1
  • BRCA2
  • Breast cancer
  • Life Sciences & Biomedicine
  • Oncology
  • Oophorectomy
  • PREVENTION
  • SURGICAL ADJUVANT BREAST
  • Science & Technology
  • THERAPY
  • Tamoxifen
  • WOMEN

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 421

end page

  • 427

volume

  • 146

issue

  • 2